Multiple randomized controlled trials have demonstrated the cardiovascular benefits of SGLT2 inhibitors, including reductions in heart failure hospitalizations and renal composite outcomes, as well as a slowing of eGFR decline [25,26]. The gene discussed is SLC5A2; the disease is heart failure.